Tissium
Tissium (formerly Gecko Biomedical) is a privately owned medical device company based in Paris that is dedicated to the rapid development and commercialization of a unique biopolymers platform.
Tissium’s first product (GB-02) is an innovative polymer for tissue healing, targeting cardiovascular reconstruction as an initial indication. The structure of GB-02 is tunable, allowing customization for various applications and tissues. Gecko’s biopolymers platform is fully industrialized and highly versatile, with potential novel applications in other fields of tissue reconstruction, such as guided tissue repair and localized drug delivery.
Tissium’s platform is based on proprietary biopolymers with unique chemical and physical properties, including high viscosity, hydrophobicity and fast “on demand” curing for precise local delivery and in situ adhesion.
Sector
Medical Devices
Strategy
Capital
Status
Live
Website
tissium.com
Related News
TISSIUM Advances Clinical Pipeline in Hernia Repair Following First FDA Authorization
TISSIUM announces U.S. commercial launch of COAPTIUM® Connect and strategic governance evolution
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in atraumatic sutureless peripheral nerve repair
TISSIUM Announces Clinical Results of COAPTIUM® CONNECT System for Atraumatic Sutureless Nerve Repair
TISSIUM strengthens executive leadership team with key appointments
First patients treated with TISSIUM’s Atraumatic Hernia Repair System
TISSIUM Raises €50M in Series D funding to finance its commercial launch and platform extension
TISSIUM appoints Sara Toyloy as independent Board member
Tissium appoints Maria Sainz as Independent Board Member
5 Sofinnova Partners portfolio companies selected to French Tech 120
TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
Tissium Receives CE Mark and Announces Manufacturing Compliance Certification from TÜV SÜD
TISSIUM Closes €39M Series B Funding Round
Gecko Biomedical secures €6 million in funding under the Investments for the Future program (Programme d’investissements d’avenir, PIA), to industrialize and develop innovative solutions for tissue re
Gecko Biomedical raises €22.5 million led by Sofinnova Partners
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.